drugset / Trial / NCT05585996
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, prospective, dose-escalation clinical trial designed to evaluate the safety and the preliminary efficacy of CD19-targeted CAR-T combined with CAR-DC in the treatment of relapsed and refractory B-cell lymphoma
Timeline
- Start
- 2022-08-01
- Primary completion
- 2025-11-01
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-DC | Cell therapy | 0.25 cells/kg | Intravenous |
| Subject | CD19 CAR-DC | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | CD19 CAR-DC | Cell therapy | 0.75 cells/kg | Intravenous |
| Subject | CD19 CAR-T | Cell therapy | 2 cells/kg | Intravenous |